When clinical trial teams screen for "tech-savvy, engaged" participants, they're often running a second, unwritten eligibility criterion that systematically excludes the populations the study drug is actually meant to treat.
Rakshinda Mujeeb, PharmD, CRCP, ACRP-CP
Advertisement
Rakshinda Mujeeb, PharmD, CRCP, ACRP-CP®, Research Projects Manager, Mediclinic Middle East.
Articles by Rakshinda Mujeeb, PharmD, CRCP, ACRP-CP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
2
Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial
3
How Selective Safety Data Collection Could Make Pragmatic Trials Scalable
4